These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25774748)

  • 1. Risk factors for progression in ADPKD.
    Alam A
    Curr Opin Nephrol Hypertens; 2015 May; 24(3):290-4. PubMed ID: 25774748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of rapid disease progression in autosomal dominant polycystic kidney disease.
    Corradi V; Gastaldon F; Caprara C; Giuliani A; Martino F; Ferrari F; Ronco C
    Minerva Med; 2017 Feb; 108(1):43-56. PubMed ID: 27701376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
    Wüthrich RP; Serra AL; Kistler AD
    Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.
    Alam A; Dahl NK; Lipschutz JH; Rossetti S; Smith P; Sapir D; Weinstein J; McFarlane P; Bichet DG
    Am J Kidney Dis; 2015 Oct; 66(4):564-76. PubMed ID: 25960302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Perrone RD; Neville J; Chapman AB; Gitomer BY; Miskulin DC; Torres VE; Czerwiec FS; Dennis E; Kisler B; Kopko S; Krasa HB; LeRoy E; Castedo J; Schrier RW; Broadbent S
    Am J Kidney Dis; 2015 Oct; 66(4):583-90. PubMed ID: 26088508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.
    King BF; Torres VE; Brummer ME; Chapman AB; Bae KT; Glockner JF; Arya K; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Dec; 64(6):2214-21. PubMed ID: 14633145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview.
    Corradi V; Gastaldon F; Virzì GM; Caprara C; Martino F; Ronco C
    Minerva Med; 2015 Feb; 106(1):53-64. PubMed ID: 25300895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
    Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
    Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment.
    Helal I; Reed B; Schrier RW
    Am J Nephrol; 2012; 36(2):162-7. PubMed ID: 22846584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges.
    Chebib FT; Perrone RD
    Adv Kidney Dis Health; 2023 May; 30(3):261-284. PubMed ID: 37088528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.
    McEwan P; Bennett Wilton H; Ong ACM; Ørskov B; Sandford R; Scolari F; Cabrera MV; Walz G; O'Reilly K; Robinson P
    BMC Nephrol; 2018 Feb; 19(1):37. PubMed ID: 29439650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease.
    Zschiedrich S; Budde K; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hoerl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Lindner TH; Faerber L; Wimmer P; Stork R; Eckardt KU; Walz G
    Nephrol Dial Transplant; 2016 Feb; 31(2):284-9. PubMed ID: 25832108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic kidney disease: a 2011 update.
    Steinman TI
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):189-94. PubMed ID: 22274800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: HOW AND WHY SHOULD WE IDENTIFY THE PATIENTS "RAPIDLY PROGRESSING" TO END-STAGE RENAL DISEASE?].
    Bodson A; Meunier P; Krzesinski JM; Jouret F
    Rev Med Liege; 2016 Apr; 71(4):184-92. PubMed ID: 27295898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
    Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
    Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress in autosomal dominant polycystic kidney disease].
    Hu S; Li D; Tan X; Gu J; Chen M; Zhang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 44(10):1179-1187. PubMed ID: 31857514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients.
    Caroli A; Antiga L; Conti S; Sonzogni A; Fasolini G; Ondei P; Perico N; Remuzzi G; Remuzzi A
    Am J Pathol; 2011 Aug; 179(2):619-27. PubMed ID: 21683674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease.
    Woon C; Bielinski-Bradbury A; O'Reilly K; Robinson P
    BMC Nephrol; 2015 Aug; 16():140. PubMed ID: 26275819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.